AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol

Axsome Therapeutics (AXSM) announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive daytime sleepiness (EDS).Axsome currently markets solriamfetol as Sunosi for treating narcolepsy.Axsome acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (JAZZ) in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.Jazz had received ap ...